Reduced expression of C/EBPα protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival

被引：34

作者：

Tseng, Hsi-Huang ^{[1
]}

Hwang, Yaw-Huei ^{[1
]}

Yeh, Kun-Tu ^{[2
]}

Chang, Jan-Gowth ^{[3
,4
]}

Chen, Yao-Li ^{[5
]}

Yu, Hsin-Su ^{[6
]}

机构：

[1] Natl Taiwan Univ, Inst Occupat Med & Ind Hyg, Coll Publ Hlth, Taipei 10764, Taiwan

[2] Changhua Christian Hosp, Dept Pathol, Changhua, Taiwan

[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan

[4] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Lab Med, Kaohsiung, Taiwan

[5] Changhua Christian Hosp, Div Gen Surg, Dept Surg, Changhua, Taiwan

[6] Kaohsiung Med Univ, Dept Dermatol, Fac Med, Kaohsiung, Taiwan

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2009年 / 135卷 / 02期

关键词：

CCAAT/enhancer binding protein alpha; Immunohistochemistry; Hepatocellular carcinoma; Survival; CCAAT/ENHANCER-BINDING-PROTEIN; ACUTE MYELOID-LEUKEMIA; CELL-PROLIFERATION; DOWN-REGULATION; ANTIPROLIFERATIVE ROLE; CEBPA MUTATIONS; LUNG-CANCER; LIVER; MICE; PATHOGENESIS;

D O I：

10.1007/s00432-008-0448-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CCAAT/enhancer binding protein alpha (C/EBP alpha) is a transcription factor and a tumor suppressor. We aimed to assess its protein expression and prognostic value in human hepatocellular carcinoma (HCC). We conducted a retrospective cohort study on 50 HCC patients and performed immunohistochemistry against C/EBP alpha on tumors and adjacent nontumor specimens. Relationships of C/EBP alpha expression with clinical parameters and patient survival were analyzed. C/EBP alpha expression was not influenced by chronic alcohol exposure, viral hepatitis, or cirrhosis, but was reduced in 60% of HCC. Reduction of C/EBP alpha was associated with advanced tumor stage (P = 0.001). Patients with markedly reduced C/EBP alpha expression had a significantly shorter survival with a hazard ratio of 5.45 (95% confidence interval, 1.93-15.40; P = 0.001). C/EBP alpha may be a potential prognostic marker or therapeutic target in HCC regardless of different etiology.

引用

页码：241 / 247

页数：7

共 38 条

[11] DIFFERENTIAL PATTERNS OF EXPRESSION OF 3 C/EBP ISOFORMS, HNF-1, AND HNF-4 AFTER PARTIAL-HEPATECTOMY IN RATS [J].

FLODBY, P ;

ANTONSON, P ;

BARLOW, C ;

BLANCK, A ;

PORSCHHALLSTROM, I ;

XANTHOPOULOS, KG .

EXPERIMENTAL CELL RESEARCH, 1993, 208 (01) :248-256

[12] CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics:: Prognostic relevance and analysis of cooperating mutations [J].

Fröhling, S ;

Schlenk, RE ;

Stolze, I ;

Bihlmayr, J ;

Benner, A ;

Kreitmeier, S ;

Tobis, K ;

Döhner, H ;

Döhner, K .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (04) :624-633

[13] Down-regulation end growth inhibitory role of C/EBPα in breast cancer [J].

Gery, S ;

Tanosaki, S ;

Bose, S ;

Bose, N ;

Vadgama, J ;

Koeffler, HP .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3184-3190

[14]

Halmos B, 2002, CANCER RES, V62, P528

[15]

HARATAKE J, 1993, CANCER, V72, P1178, DOI 10.1002/1097-0142(19930815)72:4<1178::AID-CNCR2820720408>3.0.CO

[16]

2-Q

[17] INHIBITION OF CELL-PROLIFERATION BY C/EBP-ALPHA OCCURS IN MANY CELL-TYPES, DOES NOT REQUIRE THE PRESENCE OF P53 OR RB, AND IS NOT AFFECTED BY LARGE T-ANTIGEN [J].

HENDRICKSTAYLOR, LR ;

DARLINGTON, GJ .

NUCLEIC ACIDS RESEARCH, 1995, 23 (22) :4726-4733

[18]

HIROHASHI S, 2000, WHO CLASSIFICATION T, P165

[19]

LAI CL, 1979, CANCER-AM CANCER SOC, V44, P1677, DOI 10.1002/1097-0142(197911)44:5<1677::AID-CNCR2820440522>3.0.CO

[20]

2-D

← 1 2 3 4 →